127 related articles for article (PubMed ID: 29233558)
1. Combined androgen blockade for salivary gland carcinoma.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
[No Abstract] [Full Text] [Related]
2. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
3. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
4. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Pisansky TM; Hunt D; Gomella LG; Amin MB; Balogh AG; Chinn DM; Seider MJ; Duclos M; Rosenthal SA; Bauman GS; Gore EM; Rotman MZ; Lukka HR; Shipley WU; Dignam JJ; Sandler HM
J Clin Oncol; 2015 Feb; 33(4):332-9. PubMed ID: 25534388
[TBL] [Abstract][Full Text] [Related]
5. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
7. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
8. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients.
Ismail FF; Meah N; Trindade de Carvalho L; Bhoyrul B; Wall D; Sinclair R
J Am Acad Dermatol; 2020 Nov; 83(5):1478-1479. PubMed ID: 32213304
[No Abstract] [Full Text] [Related]
9. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Van Poppel H
Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
[No Abstract] [Full Text] [Related]
10. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
11. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
12. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
[TBL] [Abstract][Full Text] [Related]
14. Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
Choi KH; Lee SR; Hong YK; Park DS
Asian J Androl; 2018; 20(3):270-275. PubMed ID: 29271399
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.
McNeel DG; Smith HA; Eickhoff JC; Lang JM; Staab MJ; Wilding G; Liu G
Cancer Immunol Immunother; 2012 Jul; 61(7):1137-47. PubMed ID: 22210552
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
19. Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer.
Mazzoni S
Int Urol Nephrol; 2016 Nov; 48(11):1837-1838. PubMed ID: 27417133
[No Abstract] [Full Text] [Related]
20. [DRUG-INDUCED INTERSTITIAL LUNG DISEASE DURING COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LEUPRORELIN ACETATE FOR PROSTATE CANCER].
Maeda K; Osafune T; Masuda Y; Takeda T; Kageyama S; Narita M; Kawauchi A
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):36-40. PubMed ID: 31956217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]